Iguratimod or T-614 Rheumatoid Arthritis Treatment Market Forecast and Analysis to 2023

Dallas, TX -- (SBWire) -- 03/18/2015 --Iguratimod (T-614) was approved in Japan in June 2012, and was subsequently launched the following September for the treatment of adults with active RA as an add-on to MTX in patients who are not adequately controlled by monotherapy (Eisai, press release, September 11, 2012). It was also approved in China in 2012. Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

Complete report is available
http://www.rnrmarketresearch.com/iguratimodt-614-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Scope

-Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on Iguratimod/T-614 including product description, safety and efficacy profiles as well as a SWOT analysis.

-Sales forecast for Iguratimod/T-614 for the top 2 countries from 2013 to 2023.

-Sales information covered for Japan and China.

Order a copy of this report at (Prices start at US $ 3495 for a single user PDF)
http://www.rnrmarketresearch.com/contacts/purchase?rname=312800

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return.

-Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

-Make more informed business decisions from insightful and in-depth analysis of Iguratimod/T-614 performance.

-Obtain sales forecast for Iguratimod/T-614 from 2013-2023 in top 2 countries (Japan and China).

1.1 List of Tables
Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 25
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 28
Table 6: EULAR 2013 Criteria for RA Remission 29
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 33
Table 8: Leading Branded Treatments for RA 2014 40
Table 9: Product Profile - Iguratimod 42
Table 10: Iguratimod SWOT Analysis, 2014 43
Table 11: Global Sales Forecasts ($m) for Iguratimod, 2013-2023 44
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 56

1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 29
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 30
Figure 5: Flowchart for the Management of RA - EULAR 2013 31

Explore more reports on Arthritis Drugs
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/arthritis-drugs